Inclusion Criteria:

          -  Multiple myeloma patients that have completed induction chemotherapy and peripheral
             blood stem cell collection (PBSC) in preparation for ASCT.

          -  Patients must have high-risk disease as defined by Gene Expression Profiling (GEP) 70
             risk score of ≥ 0.66 or GEP 80 gene score of ≥ 2.48 or metaphase cytogenetic
             abnormalities or lactate dehydrogenase (LDH) ≥ 360 U/L (Rule out hemolysis, infection
             and contact PI for clarification if any doubt).

          -  Patients must have failed prior treatment for their multiple myeloma (MM) including a
             proteasome inhibitor and immunomodulatory drug (so-called 'double refractory').
             Patients who have received prior salvage combination chemotherapy after failure of
             proteasome inhibitor and immunomodulatory drug are eligible (frank relapse at the time
             of enrollment is not required)

          -  Zubrod ≤ 2, unless solely due to symptoms of MM-related (bone) disease.

          -  Patients must have a platelet count of ≥ 20,000/μL within 30 days of enrollment,
             unless lower levels are explained by extensive bone marrow plasmacytosis or extensive
             prior therapy.

          -  Patients must be at least 18 years of age and not older than 75 years of age at the
             time of registration.

          -  must have preserved renal function as defined by a serum creatinine level of ≤ 3 mg/dL
             within 30 days of registration.

          -  Participants must have an ejection fraction by echocardiogram (ECHO) or multi-gated
             acquisition (MUGA) scan ≥ 40% within 90 days prior to registration.

          -  Patients must have adequate pulmonary function studies ≥ 50% of predicted on
             mechanical aspects and diffusion capacity (DLCO) ≥ 50% of predicted within 90 days
             prior to registration. If the patient is unable to complete pulmonary function tests
             due to MM-related pain or condition, exception may be granted if the principal
             investigator documents that the patient is a candidate for high-dose therapy.

          -  Patients must have at least 2x106 CD34+ cells/kg stored for transplant. In addition,
             there will be a 'back-up' available of 2x106 CD34+ cells/kg2x106 CD34+ cells/kg

          -  Patients must have signed an Institutional Review Board-approved informed consent and
             HIPAA authorization form.

        Exclusion Criteria:

          -  Prior allo-transplant.

          -  Prior auto-transplantation is permitted provided the patient is still presently a
             transplant candidate and at least 2 months should have passed since last
             auto-transplant

          -  History of poorly-controlled hypertension, diabetes mellitus, or any other serious
             medical illness or psychiatric illness that could potentially interfere with the
             completion of treatment according to this protocol or could be considered to be an
             exclusion criterion deemed by the PI.

          -  Patients must not have prior malignancy, except for adequately-treated basal cell or
             squamous cell skin cancer, in situ cervical cancer, or other cancer for which the
             patient has not received treatment for one year prior to enrollment. Other cancers
             will only be acceptable if the patient's life expectancy exceeds three years as
             determined by the PI.

          -  Pregnant or nursing women may not participate. Women of childbearing potential must
             have a negative pregnancy test documented within one week of registration. Women/men
             of reproductive potential may not participate unless they have agreed to use an
             effective contraceptive method.

          -  The subject may not be positive for HIV I/II or HTLV-I/II.